BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:tozorakimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of tozorakimab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06932263-1426@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20270607
DTEND;VALUE=DATE:20270608
SUMMARY:tozorakimab: Phase 2 readout est. (NCT06932263)
DESCRIPTION:tozorakimab\, phase 2\, Asthma.\nStudy: Dose Range Finding Stud
 y to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled
  Asthma on Medium-to-High Dose Inhaled Corticosteroids\nEstimated primary 
 completion: 7 June 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/tozorakimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06932263
URL:https://assetmemo.bio/drug/tozorakimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05624450-1426@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20271104
DTEND;VALUE=DATE:20271105
SUMMARY:tozorakimab: Phase 3 readout est. (NCT05624450)
DESCRIPTION:tozorakimab\, phase 3.\nStudy: Efficacy and Safety of Tozorakim
 ab in Patients Hospitalised for Viral Lung Infection Requiring Supplementa
 l Oxygen\nEstimated primary completion: 4 November 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/tozorakimab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05624450
URL:https://assetmemo.bio/drug/tozorakimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07566195-1426@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20281229
DTEND;VALUE=DATE:20281230
SUMMARY:tozorakimab: Phase 3 readout est. (NCT07566195)
DESCRIPTION:tozorakimab\, phase 3\, Chronic Obstructive Pulmonary Disease.\
 nStudy: Long-term Safety and Tolerability of Tozorakimab in Patients With 
 COPD and History of Exacerbations\nEstimated primary completion: 29 Decemb
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/tozorakimab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0756
 6195
URL:https://assetmemo.bio/drug/tozorakimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
